File downloaded on 2026-11-23
Source URL: https://medicines.health.europa.eu/veterinary/en/600000003603

Ultifend ND IBD (--) - Concentrate and solvent for suspension for injection

Authorised

- Turkey herpesvirus, strain rHVT/ND/IBD (cell-associated), encoding fusion protein gene of Newcastle disease virus and VP2 protein gene of Infectious bursal disease virus, Live

Product identification

Medicine name:
Ultifend ND IBD (--) - Concentrate and solvent for suspension for injection

Active substance:
Turkey herpesvirus, strain rHVT/ND/IBD (cell-associated), encoding fusion protein gene of Newcastle disease virus and VP2 protein gene of Infectious bursal disease virus, Live

Target species:
Chicken
Chicken (embryonated eggs)

Route of administration:
In ovo
Subcutaneous use

Product details

Active substance and strength:

Turkey herpesvirus, strain rHVT/ND/IBD (cell-associated), encoding fusion protein gene of Newcastle disease virus and VP2 protein gene of Infectious bursal disease virus, Live

Presentation_strength:4000 PFU/dose - 12000 PFU/dose Index:0

Pharmaceutical form:

Concentrate and solvent for suspension for injection

Withdrawal period by route of administration:

In ovo:

- **Chicken**
  - Not applicable. 0 day Zero days

Subcutaneous use:

- **Chicken**
  - Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI01AD16

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:
Packaging:Concentrate: ampoule (glass), solvent: bag (PVC), Package_size:1 ampoule, Content:4000 doses
Packaging:Concentrate: ampoule (glass), solvent: bag (PVC), Package_size:1 ampoule, Content:1000 doses
Packaging:Concentrate: ampoule (glass), solvent: bag (PVC), Package_size:1 ampoule, Content:2000 doses

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Ceva-Phylaxia Zrt.

Marketing authorisation date:
20/04/2021

Manufacturing sites for batch release:
Ceva-Phylaxia Zrt.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
20/04/2021

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 14/03/2026
Download